# Cardiometabolic Effects of Nigella sativa in Postmenopausal Women with Hypertension: A Prospective, Observational, Pilot Study

## TL;DR

This study shows that Nigella sativa can lower blood pressure and improve metabolic health in postmenopausal women with hypertension, especially at higher doses.

## Contribution

The study provides new evidence on the dose-dependent cardiometabolic benefits of Nigella sativa in postmenopausal women with hypertension.

## Key findings

- NS supplementation significantly reduced systolic and diastolic blood pressure in a dose-dependent manner.
- The 800 mg/day dosage led to greater reductions in weight and body mass index compared to 400 mg/day.
- Younger age and elevated baseline heart rate predicted better treatment response.

## Abstract

Background: Hypertension is a prevalent condition, impacting a significant amount of general population and contributing prominently to global mortality. Increasing attention has been directed towards phytotherapy products as potential complementary or alternative therapies for hypertension prevention and treatment. Among these, Nigella sativa (NS) has shown encouraging effects in improving cardiovascular parameters. This study aimed to evaluate the efficacy of NS supplementation in reducing seated office systolic blood pressure (BP) in postmenopausal women. We also explored the dose-dependent effects of this intervention on BP levels and metabolic parameters. Materials and Methods: We conducted an observational pilot study including 52 women, who were stratified into two active groups (n = 32) receiving two different dosages of NS (n = 16, age 54.2 ± 2.3 at 400 mg/day and n = 16, age 52.3 ± 2.4 at 800 mg/day) and a control group (n = 20, age 53.9 ± 3.0). Participants were evaluated at baseline (T0), at 4 (T1) and 8 weeks (T2) for office brachial and central BP, heart rate (HR), lipid profile, body weight, and menopausal symptoms. Results: NS supplementation significantly reduced office systolic and diastolic BP in a dose-dependent manner (p < 0.01), with more pronounced reductions at 800 mg/day. Improvements in climacteric symptoms and reduced HR were observed as early as T1, while metabolic parameters, including lipid profile and weight, showed significant changes at T2. Notably, the 800 mg/day dosage group also experienced significant reductions in weight and body mass index. Younger age, more recent menopausal transition, and elevated baseline HR were identified as predictors of a better response to treatment. Conclusions: NS supplementation demonstrates significant dose-dependent benefits in reducing office BP and improving metabolic parameters. These findings support the role of NS as an effective complementary therapy in hypertension management in postmenopausal women.